1. European Urology Oncology
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer 
Melody J. Xu, Zachary Kornberg, Adam J. Gadzinski, Dongmei Diao, Janet E. Cowan, Susan Y. Wu, Lauren Boreta, Daniel E. Spratt, Spencer C. Behr, Hao G. Nguyen, Matthew R. Cooperberg, Elai Davicioni, Mack Roach, Thomas A. Hope, Peter R. Carroll, Felix Y. Feng 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Distribution of PSMA-avid lymph node metastases between high-risk GC and low-risk GC patients. (A) Nodal stations. I=obturator; II=internal iliac; III=external iliac; IV=presacral and perirectal; V=common iliac; VI=para-aortic; VII=inguinal. (B) Frequency of nodal station distribution among 20 patients with GC high risk (total 33 nodal stations identified; left, purple) and eight patients with GC low risk (total nine nodal stations involved; right, orange). One patient with GC high risk had a PSMA-avid supraclavicular lymph node identified in addition to pelvic and para-aortic lymph nodes (data not shown). (C) Coronal PSMA PET/CT image of a patient with GC high risk with PSMA-avid nodal disease identified at numerous pelvic lymph nodes. GC=genomic classifier. PET/CT=positron emission tomography/computed tomography. PSMA=prostate specific membrane antigen.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions